Dr. Harshraj Leuva, MD

Dr. Leuva practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Leuva's NPI, 1184017618, was assigned on March 9, 2015. Dr. Leuva holds Nebraska license 34604.

Dr. Leuva's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Leuva also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Leuva's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Leuva is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Leuva to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leuva practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Leuva's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Leuva is licensed in Nebraska.

CMS data shows 553 Medicare services from Dr. Leuva across 6 procedure codes in 2024, for 149 Medicare patients. Medicare paid $47,519 for them.

CMS counts 149 Medicare patients who saw Dr. Leuva in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 74% have cancer. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leuva's median patient age at 73, with 18% women.

In 2024, Dr. Leuva wrote 780 Medicare Part D claims for 86 patients. 80% of them were for generic drugs. CMS names the drug for 586 of them, across 16 drugs with 11 or more claims each, at $2,083,905 in total drug cost. In 2023, CMS named 310 claims across 12 drugs.

Dr. Leuva accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leuva as offering telehealth.

Dmand AI links 8 papers to Dr. Leuva, published from 2019 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Veterans, Antineoplastic Combined Chemotherapy Protocols and Prostatic Neoplasms. Dr. Leuva has published most often in Semin Oncol. Dr. Leuva's most frequent co-authors are Yeun-Hee Anna Park, MD, Cynthia Elizabeth Dunbar, MD and Izak Faiena, MD.

CMS Open Payments shows 23 general payments to Dr. Leuva from 12 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 93% of the total. Astellas Pharma Global Development paid the most, $227.